Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 4/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.42 |
| ▸ | CDK2 | P24941 | 5/20 | 0.42 |
| ▸ | CDK1 | P06493 | 4/20 | 0.42 |
| ▸ | CDK7 | P50613 | 3/20 | 0.42 |
| ▸ | CDK9 | P50750 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260385 | 0.84 | BRAF (0.51) | GSK3BMAPK8ALKHDAC1HDAC6 | |
| SCHEMBL5261586 | 0.81 | IGF1R (0.48) | GSK3BALKHDAC1HDAC2HDAC6 | |
| SCHEMBL26506662 | 0.81 | GSK3B (0.58) | GSK3BMAPK8ALKIGF1RPTK2 | |
| SCHEMBL5260063 | 0.81 | TBK1 (0.63) | GSK3BIGF1RAURKATBK1CDK2 | |
| SCHEMBL26506636 | 0.79 | MAPK8 (0.56) | GSK3BMAPK8ALKIGF1RNTRK2 | |
| SCHEMBL26506627 | 0.79 | IGF1R (0.68) | GSK3BMAPK8ALKIGF1RAURKA | |
| SCHEMBL26506628 | 0.76 | CHEK1 (0.60) | GSK3BMAPK8ALKIGF1RNTRK2 | |
| SCHEMBL26506649 | 0.76 | IGF1R (0.69) | GSK3BMAPK8ALKIGF1RKDR | |
| SCHEMBL26506654 | 0.74 | MAPK8 (0.53) | GSK3BMAPK8ALKIGF1RTBK1 | |
| SCHEMBL26506639 | 0.74 | MAPK8 (0.49) | GSK3BMAPK8ALKIGF1RNTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | claimed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | claimed |
| JP-2003525278-A | — | — | 2003-08-26 | — | — | JP | claimed |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | claimed |
| EP-1268444-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-02 | — | — | EP | claimed |
| WO-2001064655-A1 | 2, 4-DI(HETERO-)ARYLAMINO (-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | GSK3B 455/4885MAPK8 666/4885ALK 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.